Cardiovascular Polypill
Phase 3Small molecule
Cardiovascular Polypill is one of 43 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
274 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Actos
TakedaPhase 3
Colcrys
Alnylam PharmaceuticalsPhase 3
Byetta
AstraZenecaPhase 3
Zocor
OOrganon and Co
Phase 3
Repatha
AmgenPreclinical
Cardiovascular Polypill
FFundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Phase 3
Praluent
RegeneronPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Benicar
NovartisPreclinical
Farxiga
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cardiovascular Polypill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details